Avandia News

GlaxoSmithKline announces the approval and availability of AVANDARYL(rosiglitazone maleate and glimepiride): A new fixed-dose combination tablet to treat Type 2 diabetes
GlaxoSmithKline announces the approval and availability of AVANDARYL(rosiglitazone maleate and glimepiride): A new fixed-dose combination tablet to treat Type 2 diabetes New product offers a convenient option that combines rosiglitazone, an insulin sensitizer, with a sulfonylurea to help patients improve blood sugar control Issued – 1st ...

New data show Avandia ® (rosiglitazone maleate) may reduce blood pressure, an important cardiovascular risk factor, in type 2 diabetes patients
New data show Avandia® (rosiglitazone maleate) may reduce blood pressure, an important cardiovascular risk factor, in type 2 diabetes patients SAN DIEGO, CA - June 11, 2005 – New research presented today at the 65th Annual Scientific Sessions of the American Diabetes Association (ADA) suggests that Avandia ® (rosiglitazone maleate), a ...

GlaxoSmithKline reviews novel therapeutics for CNS disorders and confirms strong pipeline momentum
GlaxoSmithKline reviews novel therapeutics for CNS disorders and confirms strong pipeline momentum Issued – Tuesday 23 November 2004, London Today GlaxoSmithKline [NYSE: GSK] gave investors and financial analysts an update on its compounds in development to treat Central Nervous System disorders, a therapy area that represents approximately 20% ...

GlaxoSmithKline receives approval from the European Commission for new strengths of Avandamet for the treatment of type 2 diabetes
GlaxoSmithKline receives approval from the European Commission for new strengths of Avandamet for the treatment of type 2 diabetes Not for distribution to US Media Issued – Wednesday 8th September 2004 New dosage strengths to provide increased dosing flexibility for managing type 2 diabetes GlaxoSmithKline plc [LSE and NYSE: GSK] announced ...

GlaxoSmithKline posts data on Clinical Trial Register
GlaxoSmithKline posts data on Clinical Trial Register Philadelphia, PA (September 1, 2004) — GlaxoSmithKline (NYSE: GSK) announced today that it has posted the first set of data on the GSK Clinical Trial Register, a Web site that facilitates access to information derived from GSK-sponsored clinical trials. The Register provides summary results ...

GlaxoSmithKline receives positive opinion from EMEAs CHMP for use of new strength Avandamet ™ as treatment for type 2 diabetes
GlaxoSmithKline receives positive opinion from EMEA's CHMP for use of new strength Avandamet™ as treatment for type 2 diabetes Not for distribution to US Media Issued — Monday 7 June 2004, London New dosage strengths to offer physicians and patients dosing flexibility for managing type 2 diabetes GlaxoSmithKline plc [LSE and NYSE: GSK] ...

New data show Avandia ® (rosiglitazone maleate) may reduce risk for type 2 diabetes and cardiovascular disease in African Americans and Hispanic Americans
New data show Avandia® (rosiglitazone maleate) may reduce risk for type 2 diabetes and cardiovascular disease in African Americans and Hispanic Americans FOR IMMEDIATE RELEASE Contact: Bernadette King GlaxoSmithKline 215-751-3632 Janet Graesser Cohn & Wolfe 212-798-9771 917-685-8799 (on-site) Significant ...

GlaxoSmithKline launches national corporate ad campaign
GlaxoSmithKline launches national corporate ad campaign Philadelphia, PA, March 15, 2004 - GlaxoSmithKline [NYSE: GSK] today launched a corporate ad campaign that highlights the company's investment in pharmaceutical research and development, and publicizes its senior savings program. The ads will run nationally in television and print media beginning ...

GlaxoSmithKline unveils a broad R&D pipeline of innovative science and class-leading compounds
GlaxoSmithKline unveils a broad R&D pipeline of innovative science and class-leading compounds London, December 3, 2003 - At a presentation to investors today, GlaxoSmithKline demonstrated that the company’s unique R&D structure is delivering a large and diverse pipeline. GSK now has 147 projects in clinical development, spanning a variety of ...

GlaxoSmithKline receives authorisation from EC for Avandia as oral monotherapy for treatment of type 2 diabetes
GlaxoSmithKline receives authorisation from EC for Avandia as oral monotherapy for treatment of type 2 diabetes London, September 2, 2003 - GlaxoSmithKline announced today it has received marketing authorisation from the European Commission for use of Avandia (rosiglitazone maleate) as oral monotherapy in type 2 diabetes patients, particularly ...

GSK announcement on worldwide trial into cardiovascular disease
GSK announcement on worldwide trial into cardiovascular disease London, September 1, 2003 - GlaxoSmithKline today announce co-sponsorship* of one of the world’s largest ever drug trials into cardiovascular disease, the leading cause of death in the developed world. Comprising over 29,000 patients across 700 locations worldwide, The ONTARGETTM ...

FDA approves new Avandamet ™ (rosiglitazone maleate and metformin HCl) dosage strengths for the treatment of type 2 diabetes
FDA approves new Avandamet™ (rosiglitazone maleate and metformin HCl) dosage strengths for the treatment of type 2 diabetes New dosage strengths offer physicians and patients dosing dlexibility dor managing type 2 diabetes Philadelphia, PA, August 27, 2003 - GlaxoSmithKline (NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) ...

Study suggests the early addition of Avandia ™ (rosiglitazone maleate) significantly improves blood sugar levels in elderly type 2 diabetes patients
Study suggests the early addition of Avandia™ (rosiglitazone maleate) significantly improves blood sugar levels in elderly type 2 diabetes patients Fifty percent of elderly patients reached and maintained recommended American Diabetes Association target blood sugar levels for two years Philadelphia, PA, August 28, 2003 — Data presented at the ...

GlaxoSmithKline receives positive opinion from EMEA’s CPMP for use of Avandamet ™ as treatment for Type 2 Diabetes
GlaxoSmithKline receives positive opinion from EMEA’s CPMP for use of Avandamet™ as treatment for Type 2 Diabetes AVANDAMET combines two complementary treatments in one pill for improved glucose control London, June 27, 2003 - GlaxoSmithKline plc [LSE and NYSE: GSK] announced today it has received a positive opinion from the European Agency for the ...

New studies suggest Avandia ® may provide certain cardiovascular disease benefits
New studies suggest Avandia® may provide certain cardiovascular disease benefits New Orleans, LA, June 17, 2003 - In two separate studies, data presented at the 63rd Annual Scientific Sessions of the American Diabetes Association showed that the insulin sensitizer Avandiaâ (rosiglitazone maleate) may provide cardiovascular disease benefits in ...

Avandia ® receives positive CPMP opinion for oral monotherapy in defined population of patients with type 2 diabetes
Avandia® receives positive CPMP opinion for oral monotherapy in defined population of patients with type 2 diabetes London, May 23, 2003 - GlaxoSmithKline plc [LSE and NYSE: GSK] announced today it has received a positive opinion from the European Committee for Proprietary Medicinal Products (CPMP) for use of Avandia® (rosiglitazone) in the ...

FDA approves Avandia ® (rosiglitazone maleate) for use in combination with insulin for the treatment of type 2 diabetes
FDA approves Avandia® (rosiglitazone maleate) for use in combination with insulin for the treatment of type 2 diabetes Philadelphia, PA, March 3, 2003 - GlaxoSmithKline (NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) approved Avandia® (rosiglitazone maleate) for use in combination with insulin for the treatment of type ...

GlaxoSmithKline calls for passage of Medicare prescription drug benefit
GlaxoSmithKline calls for passage of Medicare prescription drug benefit Philadelphia, February 20, 2003 -- In a statement released today, GlaxoSmithKline encouraged all Americans concerned about affordability of prescription medicines to contact their Member of Congress and urge their support for passage of a Medicare prescription drug ...

GlaxoSmithKline announces FDA approval and the launch of Avandamet® (rosiglitazone maleate and metformin HCl) as inital therapy in the treatment of type 2 diabetes
GlaxoSmithKline announces FDA approval and the launch of Avandamet® (rosiglitazone maleate and metformin HCl) as inital therapy in the treatment of type 2 diabetes Avandamet combines two oral agents - rosiglitazone, the most widely used insulin sensitizer, with a leading diabetes therapy, metformin - to help patients improve blood sugar control ...

GlaxoSmithKline Responds to NEJM Article on Avandia
PHILADELPHIA, May 21 GlaxoSmithKline (NYSE: GSK) today issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia(R) (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes:    GSK strongly disagrees with the conclusions reached in the NEJM article, which are based on ...

Statement from the American College of Cardiology, American Diabetes Association and American Heart Association Related to NEJM article, Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Study raises concerns; Groups advise patients with diabetes to talk to     their doctor     ALEXANDRIA, Va., May 21 /-USNewswire/ -- The following is a Statement from the American College of Cardiology, American Diabetes Association and American Heart Association Related to NEJM article, 'Effect of ...

GlaxoSmithKline Strongly Defends its Record on Avandia
PHILADELPHIA, May 21 The following is GlaxoSmithKline's (NYSE: GSK) response to a press release issued by the US Senate Committee on Finance about Avandia(R) (rosiglitazone maleate):    The suggestion that GlaxoSmithKline has placed patients at risk and attempted to silence independent investigation of data is absolutely false. Any fair ...

Avandia Heart Attack Risk Underscores Need for Urgent Drug Safety Reform
Consumers Union urges the House to pass strong drug safety reforms now     WASHINGTON, May 21 /-USNewswire/ -- A new analysis that the top-selling oral diabetes drug Avandia - which has been on the market for eight years - may significantly increase the risk of heart attack in patients again underscores the urgent need for Congress to pass ...

GlaxoSmithKline Response to New England Journal of Medicine Editorials
PHILADELPHIA, June 5 The following is GlaxoSmithKline's (NYSE: GSK) response to editorials written in the New England Journal of Medicine (NEJM) regarding Avandia for the treatment of type 2 diabetes.    We believe the NEJM editorials are selective in their use of data to support a biased view, and therefore do a disservice to ...

Statement of Moncef Slaoui, PhD, Chairman Research & Development GlaxoSmithKline
Moncef Slaoui Testimony before the House Committee on Oversight and     Government Reform June 6, 2007     PHILADELPHIA, June 6     Statement of Moncef Slaoui, PhD, Chairman Research & Development GlaxoSmithKline    Moncef Slaoui Testimony before the House Committee on ...

Texas Family Sues GlaxoSmithKline (GSK) Over Mans Heart Attack Death Following Avandia Use
Husband died the same day Avandia heart attack dangers were published     DALLAS, June 20 // -- The widow and son of a Beaumont, Texas, man are suing drug manufacturer GlaxoSmithKline (NYSE: GSK) based on claims that the popular diabetes drug Avandia(R) contributed to the man's fatal heart attack.    The lawsuit filed in the ...

GlaxoSmithKline Presents Avandia Data To FDA
PHILADELPHIA, July 30 The following summarizes GlaxoSmithKline's [NYSE: GSK] presentation of data on Avandia(R) (rosiglitazone maleate) to an Advisory Committee of the Food and Drug Administration (FDA) on July 30, 2007.    The GSK presentation demonstrates the weight of scientific evidence available to address a question of increased risk of ...

GlaxoSmithKline Updates Prescribing Information for Avandia
PHILADELPHIA, Aug. 14 GlaxoSmithKline (NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved updated US prescribing information for the thiazolidinediones (TZD) class of medicines used in the treatment of Type 2 diabetes. This approval allows GSK to implement changes in the label for Avandia(R) (rosiglitazone maleate) as previously ...

Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
Results Appear in the Sept. 12 Issue of the Journal of the American Medical     Association     CLEVELAND, Sept. 11 // -- A drug widely used to treat type 2 diabetes has been found to reduce the risk of death, heart attack (myocardial infarction) or stroke when used alone or in combination with other ...

GlaxoSmithKline Responds to JAMA Articles
PHILADELPHIA, Sept. 11 GlaxoSmithKline (NYSE: GSK) believes that conclusions drawn from the most recent meta-analyses published by Drs. Nissen et. al. and Furberg et. al. in the Journal of the American Medical Association (JAMA) do not confirm a difference in the safety profile of Avandia(R) (rosiglitazone) and Actos(R) (pioglitazone). These analyses reflect ...

Vanda Pharmaceuticals Hires Chief Commercial Officer
ROCKVILLE, Md., Oct. 23 Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced that Al Gianchetti will join the Company as Senior Vice President and Chief Commercial Officer effective October 25, 2007. Mr. ...

Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
PALO ALTO, Calif., Oct. 24 // -- Vivo Ventures, a venture capital firm specializing in life science investments, today announced that James Huang will join the firm as an Executive in Residence. With his extensive business development and operating experience, Mr. Huang will work with Vivo's portfolio companies while enhancing the firm's presence ...

GSK Revises US Labeling for Avandia(R)
LONDON and PHILADELPHIA, Nov. 14 GlaxoSmithKline announced today that it is implementing changes to the US product label for Avandia(R) (rosiglitazone maleate), based on an extensive and thorough review by the FDA of myocardial ischemia data on Avandia, the most widely studied oral anti-diabetic medicine available.    The existing boxed warning has ...

Treating Depression Prolongs Life for Older People with Diabetes
Also This Month: Lessons Learned from the Avandia Controversy     ALEXANDRIA, Va., Nov. 27 /-USNewswire/ -- Depressed, older adults with diabetes live longer when they are treated for depression, according to a study in the December issue of Diabetes Care, which publishes on November 27, 2007.     Also being published this ...

The Top 10 Health Stories of 2007, From the Editors of the Harvard Health Letter
BOSTON, Dec. 3 /-USNewswire/ -- The editors of Harvard Medical School's Harvard Health Letter have chosen the top 10 health stories of 2007. Here are this year's newsmakers:     1. Drug safety failures. This year, rosiglitazone (Avandia), a diabetes drug, became the latest medication found to have serious side effects that weren't apparent when ...

Endocrinology Panel Examines Interplay Between Diabetes and Cardiovascular Disease in New Report
SCOTTSDALE, Ariz., Dec. 4 // -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for T2 diabetes therapies.     In this report, entitled "MedPredict Thought Leader ...

Safety Concerns Prompt Prime to Remove Avandia(R) from Formulary
ST. PAUL, Minn., Dec. 6 // -- Pharmacy benefit manager Prime Therapeutics (Prime) recently announced the removal of the prescription drug Avandia(R) from its national formulary. After careful examination of clinical literature regarding the safety and efficacy of Avandia, Prime's National Pharmacy and Therapeutics (P&T) Committee has made the decision to remove the ...

More evidence suggests diabetes drug may be dangerous
TORONTO, Dec. 11 - - A popular class of drugs for treating type 2 diabetes is under scrutiny again. A new Canadian study released by the Institute for Clinical Evaluative Sciences (ICES) finds that drugs such as Avandia increase the risk of heart failure, heart attacks and death. Published in the December 12th issue of JAMA, ICES scientists looked at the ...

Major Pharma Clinical Case Studies from Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School during 1st Quarter ExL Pharma Programs
NEW YORK, Dec. 11 // -- ExL Pharma brings in the New Year with a variety of educational and networking opportunities addressing the leading issues facing the pharmaceutical industry in 2008. These market-derived events target executives in Clinical, R&D, Regulatory, Medical Affairs and Marketing from large to small pharmaceutical, biotech, device and medical technology ...

GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
PHILADELPHIA, Dec. 11 The following is GlaxoSmithKline's (NYSE: GSK) response to the retrospective analysis by the Institute for Clinical Evaluative Sciences (ICES) titled "Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes".     GSK believes that the ICES retrospective analysis of the Ontario Drug Benefit (ODB) ...

More evidence suggests diabetes drug may be dangerous
TORONTO, Dec. 11 // - A popular class of drugs for treating type 2 diabetes is under scrutiny again. A new Canadian study released by the Institute for Clinical Evaluative Sciences (ICES) finds that drugs such as Avandia increase the risk of heart failure, heart attacks and death.     Published in the December 12th issue of JAMA, ICES scientists ...

Patient Denial is the Primary Reason Asthma Sufferers Do Not Fill Prescription After Diagnosis
Merck/Kyorin's Singulair Has Posted Large Gains in Second-line Patient     Share, and GlaxoSmithKline's Advair Faces New Competition from AstraZeneca's Symbicort, According to a New Report from Decision Resources     WALTHAM, Mass., Dec. 18 // -- Decision Resources, one of the world's leading research and advisory firms ...

GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
PHILADELPHIA, Oct. 30 GlaxoSmithKline (NYSE: GSK) today issued the following response to a petition filed by Public Citizen to the U.S. Food and Drug Administration (FDA) on AVANDIA(R) (rosiglitazone maleate), a highly effective therapy for treating type 2 diabetes when used in the appropriate patient population.     The safety of patients using ...

lexdon

 

 

 


© 2001 - 2015 Lexdon Business Library
TrustBase Registration
Privacy Policy
eTrust Privacy Certified